Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, vol.22, pp.320-330, 2015. ,
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, vol.16, pp.375-384, 2015. ,
Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma, J Clin Oncol, vol.34, pp.4102-4109, 2016. ,
Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl www.medicaljournals.se/acta, J Med, vol.375, pp.819-829, 2016. ,
PD-L1 expression as a predictive biomarker in cancer immunotherapy, Mol Cancer Ther, vol.14, pp.847-856, 2015. ,
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma, Br J Cancer, vol.114, pp.256-261, 2016. ,
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Oncotarget, vol.7, pp.77404-77415, 2016. ,
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab, Clin Cancer Res, vol.22, pp.2908-2918, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01409624
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, vol.22, pp.5487-5496, 2016. ,
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma, Br J Dermatol, vol.174, pp.146-151, 2016. ,
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann Oncol, vol.27, pp.732-738, 2016. ,
Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, vol.27, pp.6199-6206, 2009. ,
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7420, 2009. ,
Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011. ,
The prognostic value of baseline lymphocyte, neutrophil, and monocyte counts in locally advanced cervical carcinoma treated with radiation, Obstet Gynecol Int, p.8584605, 2017. ,
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients, Cancer Biol Ther, vol.14, pp.469-475, 2013. ,
Agency for Healthcare Research and Quality (US), 2013. ,
,